Construction of a Gene Bank of Hup+ Rhizobium Japonicum Strain CB1003 in a Broad Host Range Cloning Cosmid Vector

Author(s):  
Tomás Ruiz-Argüeso
1985 ◽  
Vol 31 (3) ◽  
pp. 220-223 ◽  
Author(s):  
Thomas J. McLoughlin ◽  
P. Ann Owens ◽  
Scott G. Alt

The ability of eight fast-growing strains of Rhizobium japonicum to compete for nodule sites against two slow-growing strains of R. japonicum was measured using different input ratios (1:1, 1:10, and 10:1) on Glycine max cv. Peking and cv. Jacques 130 in growth pouches. The slow growers formed >60% of the nodules on cv. Peking even when the fast growers were added at a 10:1 ratio in their favor. We also measured the competitive ability of 10 fast-growing strains of R. japonicum, including these 8 strains, and ANU240 (a fast-growing broad host range strain) at two inoculum levels, 106 and 109 cells/seed on cv. Peking and cv. Jacques 130 in pots containing two midwestern soils which contained high numbers of indigenous rhizobia. In one soil, 3 of the 10 fast-growing strains occupied >60% of the nodules on cv. Peking at 109 inoculum level. No nodules were formed by the fast-growing strains on cv. Jacques 130 in any of the experiments.


2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S801-S801
Author(s):  
Jose Alexander ◽  
Daniel Navas ◽  
Marly Flowers ◽  
Angela Charles ◽  
Amy Carr

Abstract Background With the rise of the antimicrobial resistance between different genera and species of bacteria, Phage Therapy is becoming a more realistic and accessible option for patients with limited or no antimicrobial options. Being able to have rapid access to a collection of clinical active phages is key for rapid implementation of phage therapy. The Microbiology Department at AdventHealth Orlando is performing routine screening of environmental and patient samples for isolation of phages against non-fermenting Gram negative bacteria to develop a Phage Bank. Methods Protocols for phage isolation from environmental sources such as lakes, rivers and sewers and clinical samples were developed. A series of respiratory, throat, stool and urine samples were processed following an internal protocol that includes centrifugation, filtration and enrichment. Clinical samples were centrifugated for 10 minutes, filtered using 0.45µm centrifugation filters, seeded with targeted host bacteria (clinical isolates) and incubated at 35°C for 24 hours. The enriched samples were centrifugated and filtered for a final phage enriched solution. Screening and isolation were performed using the Gracia method over trypticase soybean agar (TSA) for plaque morphology and quantification. Host range screening of other clinical isolates of P. aeruginosa was performed using the new isolated and purified phages. Results 4 lytic phages against clinical strains of P. aeruginosa from patient with diagnosis of cystic fibrosis (CF), were isolated and purified from 4 different respiratory samples, including sputum and bronchial alveolar lavage. All phages showed phenotypical characteristics of lytic activity. 1 phage was active against 4 strains of P. aeruginosa, 1 phage was active against 2 strains of P. aeruginosa and the remaining 2 phages were active only against the initial host target strain. Conclusion With this study we demonstrated the potential use of clinical samples as source for isolating active bacteriophages against clinically significant bacteria strains. Clinical samples from vulnerable population of patients with chronic infections are part of our routine “phage-hunting” process to stock and grow our Phage Bank project for future clinical use. Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document